Deenova Wins First Private Contract in Spain for Hospital Centro de Andalucía de Lucena
14.4.2021 09:00:00 EEST | Business Wire | Press release
Deenova announced today that its unrivalled market momentum unceasingly expands to Spain´s private hospital market, with its first award for won by Deenova in cooperation with Algalasa at Hospital Centro de Andalucía at Lucena, Cordoba, part of the new health enterprise Amaveca Salud.
Gaspar G. De Viedma, Vice Chairman of the Deenova Board of Directors stated:
“I am happy to see the first results of the Deenova´s cooperation with our partnership with Algalasa in such a short period of time, and together with our prior award at Bellvitge University Hospital in Barcelona to demonstrate once again Deenova´s unique scalability in hospitals ranging from 100 to 2.000 beds, with the installation of the ACCED and ASTUS mechatronic medication solutions in 2022.”
Jose Luis Temes, M.D., Algalasa’s President and former Sub-secretary of Health at Spain Ministry of Health, Director of National Health Service in Spain, and Managing Director of multiple Spanish hospitals, including Foundation Jimenez Diaz, Hospital La Paz, and Hospital Queen Sofia, added: “This milestone was possible thanks to the hospital owners understanding of the importance of closing the loop of the medication, from prescripti<on to patient administration, and the unique Deenova’s technology. Centro de Andalucía in Lucena will be a reference in patient safety, staff satisfaction, quality and efficiency of pharmacy processes.”
Hospital Centro de Andalucía de Lucena is located in the Andalucian city of Lucena in Cordoba. With 350 employees serving up to 200 beds, including surgery, a diagnostic area, analysis, a day hospital and physiotherapy, among other services. Its innovative new construction has been equipped with all kinds of details, such as domotic rooms, and patient entertainment systems (tablets, televisions, etc).
Deenova is the undisputed leading supplier of mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006013/en/
Contact information
Deenova:
Christophe Jaffuel, Elisa Mariotti
e.mariotti@deenova.com, +39 0523 785311
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
K-Beauty Goes Global: Sales Surge 53% as Korean Innovation Reshapes Beauty Growth15.7.2026 17:00:00 EEST | Press release
NIQ (NYSE: NIQ), a global leader in consumer intelligence, today released new findings showing K-Beauty has become a rapidly growing global beauty segment, with value sales up 53% year-over-year and 131% over the past two years. The data points to a broader shift in beauty growth, as regional innovation, social commerce and digitally driven consumer demand increasingly shape what scales globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715867578/en/ K-Beauty accelerates across global markets In its latest report, K-Beauty Goes Global, NIQ shows how Korean beauty is reshaping consumer expectations, accelerating innovation cycles and redefining competitive dynamics across the global beauty market. What began as a culturally driven trend now offers a broader signal about the future of beauty: regional trends are increasingly driving global opportunity, and brands need timely intelligence to know which signals will sca
Stonebranch Recognized as a Representative Vendor in the 2026 Gartner ® Market Guide for Infrastructure Automation and Orchestration Tools15.7.2026 16:00:00 EEST | Press release
Stonebranch, a leading provider of service orchestration and automation solutions, today announced it has been recognized as a Representative Vendor in the 2026 Gartner Market Guide for Infrastructure Automation and Orchestration (IA&O) Tools.* “Stonebranch is honored to be recognized in Gartner’s 2026 Market Guide for IA&O Tools,” said Giuseppe Damiani, Stonebranch CEO. “AI, platform engineering, and hybrid infrastructure are changing how organizations operate, and we’re excited to help our customers navigate that shift with a unified platform for intelligent orchestration.” The 2026 Market Guide reflects an evolution in the IA&O market, emphasizing infrastructure orchestration as a foundational capability for platform engineering, AI infrastructure, and modern hybrid IT operations. Gartner also notes that organizations are increasingly adopting platforms that provide low-code interfaces, AI capabilities, and AI agents to accelerate automation adoption and improve operational efficien
Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage15.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to potentially improve functional patient outcomes. The study aims to initiate both randomization and surgical intervention within 120 minutes of key clinical time points, reflecting the urgent nature of intracerebral hemorrhage care. Participating sites will have the ability to leverage the Viz Neuro Suite platform, including Viz ICH and Viz ICH Plus, to support rapid identification, triage, and care coordination for potentially eligible patients across participating centers. Viz Neuro Suite combines AI-powered imaging analysis with
Accertify's Q2 Global Air Travel Fraud Report Finds Fraud Pressure Intensifying Across Middle East and Africa15.7.2026 14:00:00 EEST | Press release
Accertify, a leading fraud decisioning provider whose Predictive Yes Platform helps merchants say yes to more good customers, more revenue, and more growth, today announced the release of its Global Air Travel Fraud Report: Q2 2026, a quarterly analysis examining how fraud pressure varies across global airline markets based on departure city at time of booking. Based on analysis of 132.9 million airline booking transactions processed between April and June 2026, the report evaluates prevented fraud rates across 537 departure cities that each processed at least 10,000 transactions during the quarter, providing airlines with a data-driven view of where Accertify's Predictive Yes platform intervened most frequently at booking. The Q2 findings reveal that fraud pressure continues to vary significantly by market, with the most notable shift occurring across the Middle East and Africa. The region's average prevented fraud rate more than doubled quarter over quarter, from 0.95% to 2.03% — the
Forrester’s 2027 Budget Planning Guides: After A Year Of Caution, Business And Tech Leaders Are Ready To Invest Again15.7.2026 12:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 Budget Planning Guides, business and technology leaders are approaching 2027 with renewed confidence as they increasingly accept volatility as a permanent feature of the business environment. After a year of more cautious spending, more than 80% of leaders expect their budgets to increase over the next 12 months, with as many as one-quarter anticipating growth of 10% or more. But planning in the age of AI demands more than bigger budgets: Increasing investment without modernizing operating models, strengthening data foundations, and improving AI readiness will only accelerate fragmented data, duplicated work, and technical debt. To realize AI’s full potential, leaders must rethink their strategies and prioritize investments in operational foundations, governance, and experimentation that drive tangible outcomes. This year, optimism is widespread across functions: 82% of technology decision-makers and 91% of marketers expect budget increases
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom